Differential Effects of Sulfated Triterpene Glycosides, Holothurin A1, and 24-Dehydroechinoside A, on Antimetastasic Activity via Regulation of the MMP-9 Signal Pathway

Journal of Food Science

Volumn 75, Issue 9, 2010, Pages

  Zhao, Qin ^a   Xue, Yong ^a   Liu, Zhi Dong ^a   Li, Hui ^a   Wang, Jing Feng ^a   Li, Zhao Jie ^a   Wang, Yu Ming ^a   Dong, Ping ^a   Xue, Chang Hu ^a  

^a OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

24 dehydroechinoside A; Holothurin A1; Metastasis; MMP 9; Triterpene glycosides

Indexed keywords

24 DEHYDROECHINOSIDE A; 24-DEHYDROECHINOSIDE A; ANTINEOPLASTIC AGENT; COLLAGEN; DRUG DERIVATIVE; ECHINODERM TOXIN; GELATINASE B; GLYCOSIDE; HOLOTHURIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ; MATRIGEL; PROTEOGLYCAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRITERPENE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL; ARTICLE; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CELL STRAIN HEPG2; CHEMISTRY; CHICK EMBRYO; CHORIOALLANTOIS; COMPARATIVE STUDY; DOWN REGULATION; DRUG COMBINATION; DRUG EFFECT; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PRENATAL DEVELOPMENT; SEA CUCUMBER; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COLLAGEN; DOWN-REGULATION; DRUG COMBINATIONS; ENDOTHELIAL CELLS; GLYCOSIDES; HEP G2 CELLS; HOLOTHURIN; HUMANS; LAMININ; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTEOGLYCANS; SEA CUCUMBERS; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSCRIPTION, GENETIC; TRITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

HOLOTHUROIDEA; PEARSONOTHURIA GRAEFFEI;

EID: 78149362666     PISSN: 00221147     EISSN: 17503841     Source Type: Journal    
DOI: 10.1111/j.1750-3841.2010.01837.x     Document Type: Article

References (52)

1. Alferez D, Wilkinson R, Watkins J, Poulsom R, Mandir N, Wedge S, Pyrah I, Smith N, Jackson L, Ryan A. 2008. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in apcmin/+ mice. Mol Cancer Ther 7(3):590-8.
2. Arvelo F, Cotte C. 2006. Metalloproteinases in tumor progression: review. Investigaci 3n cl nica 47(2):185-205.
3. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. 2003. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63(17):5224-9.
4. Bergers G, Brekken R, Mcmahon G, Vu T, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737-44.
5. Bond M, Fabunmi R, Baker A, Newby A. 1998. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κb. FEBS Lett 435(1):29-34.
6. Bond M, Chase A, Baker A, Newby A. 2001. Inhibition of transcription factor NF-kappa b reduces matrix metalloproteinase-1, -3 and-9 production by vascular smooth muscle cells. Cardiovas Res 50(3):556-65.
7. Brew K, Dinakarpandian D, Nagase H. 2000. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta/Prot Struct Mol Enzymol 1477(1-2):267-83.
8. Chase A, Bond M, Crook M, Newby A. 2002. Role of nuclear factor-kappa b activation in metalloproteinase-1, -3, and-9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 22(5):765-71.
9. Chludil H, Muniain C, Seldes A, Maier M. 2002. Cytotoxic and antifungal triterpene glycosides from the patagonian sea cucumber hemoiedema spectabilis. J Nat Prod 65(6):860-5.
10. Dai L, Gu L, Ding C, Qiu L, Di W. 2009. Tweak promotes ovarian cancer cell metastasis via nf-κb pathway activation and VEGF expression. Cancer Lett 283(2):159-67.
11. Das A, Fanslow W, Cerretti D, Warren E, Talarico N, Mcguire P. 2003. Angiopoietin/tek interactions regulate mmp-9 expression and retinal neovascularization. Lab Investigat 83(11):1637-45.
12. Dong P. 2009. Studies on the isolation, identification, structure-modification and bioactivities of triterpene glycosides in pearsonothria graeffei. Ocean Univ. of China, China.
13. Epstein F. 1997. Nuclear factor-κb-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-71.
14. Ferrara N, Gerber H, Lecouter J. 2003. The biology of VEGF and its receptors. Nat Med 9(6):669-76.
15. Geho D, Bandle R, Clair T, Liotta L. 2005. Physiological mechanisms of tumor-cell invasion and migration. Physiology 20:194-200.
16. Haefner B. 2003. Drugs from the deep: marine natural products as drug candidates. Drug Discov Today 8(12):536-44.
17. Heissig B, Hattori K, Friedrich M, Rafii S, Werb Z. 2003. Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol 10(2):136-41.
18. Hornebeck W, Lambert E, Petitfrère E, Bernard P. 2005. Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. Biochimie 87(3-4):377-83.
19. Imanaka H, Koide H, Shimizu K, Asai T, Kinouchi Shimizu N, Ishikado A, Makino T, Oku N. 2008. Chemoprevention of tumor metastasis by liposomal β-sitosterol intake. Biol Pharma Bull 31(3):400-4.
20. Jiang Y, Goldberg I, Shi Y. 2002. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21(14):2245-52.
21. Jin JO, Shastina VV, Shin SW, Xu Q, Park JI, Rasskazov VA, Avilov SA, Fedorov SN, Stonik VA, Kwak JY. 2009. Differential effects of triterpene glycosides, frondoside a and cucumarioside a2-2 isolated from sea cucumbers on caspase activation and apoptosis of human leukemia cells. FEBS Lett 583(4):697-702.
22. Kohn E, Liotta L. 1995. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55(9):1856-62.
23. Lee M, Murphy G. 2004. Matrix metalloproteinases at a glance. J Cell Sci 117(18):4015-6.
24. Leung D, Cachianes G, Kuang W, Goeddel D, Ferrara N. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935):1306-9.
25. Leung D, Abbenante G, Fairlie D. 2000. Protease inhibitors: current status and future prospects. J Med Chem 43(3):305-41.
26. Liaw L, Almeida M, Hart C, Schwartz S, Giachelli C. 1994. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circulat Res 74(2):214-24.
27. Liu B, Yi Y, Li L, Zhang S, Han H, Weng Y, Pan M. 2007. Arguside a: a new cytotoxic triterpene glycoside from the sea cucumber bohadschia argus jaeger. Chem Biodiv 4(12):2845-51.
28. Mccawley L, Matrisian L. 2000. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6(4):149-56.
29. Moon S, Cha B, Kim C. 2004. Erk1/2 mediates tnf-a-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of nf-kb and ap-1: involvement of the RAS dependent pathway. J Cell Physiol 198(3):417-27.
30. Murono S, Yoshizaki T, Sato H, Takeshita H, Furukawa M, Pagano J. 2000. Aspirin inhibits tumor cell invasiveness induced by epstein-barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res 60(9):2555-61.
31. Nagao N, Etoh T, Yamaoka S, Okamoto T, Miwa N. 2000. Enhanced invasion of tax-expressing fibroblasts into the basement membrane is repressed by phosphorylated ascorbate with simultaneous decreases in intracellular oxidative stress and nf-κ b activation. Antioxid Redox Signal 2(4):727-38.
32. Nagase H, Woessner Jr J. 1999. Matrix metalloproteinases. J Biol Chem 274(31):21491-4.
33. Newman D, Cragg G. 2004. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 67:1216-38.
34. Ogawa K, Chen F, Kuang C, Chen Y. 2004. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-β is mediated by a nuclear factor-κb site. Biochem J 381(Pt 2):413-22.
35. Pepper M. 2001. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21(7):1104-17.
36. Petitclerc E, Boutaud A, Prestayko A, Xu J, Sado Y, Ninomiya Y, Sarras M, Hudson B, Brooks P. 2000. New functions for non-collagenous domains of human collagen type IV. J Biol Chem 275(11):8051-61.
37. Skehan P, Storeng R, Scudiero D, Monks A, Mcmahon J, Vistica D, Warren J, Bokesch H, Kenney S, Boyd M. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J the Nat Cancer Insti 82(13):1107-12.
38. Sternberg C. 2003. Metastatic bladder cancer: Role of chemotherapy and new agents. EAU Update Series 1(2):108-17.
39. Sternlicht M, Werb Z. 2001. How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Develop Biol 17(1):463-516.
40. Sugiyama T, Sadzuka Y. 1999. Combination of theanine with doxorubicin inhibits hepatic metastasis of m5076 ovarian sarcoma. Clinic Cancer Res 5(2):413-22.
41. Supuran C, Scozzafava A. 2002. Matrix metalloproteinases (MMPS). In: Smith HJ, Simons C, editors. Proteinase and peptidase inhibition: recent potential targets for drug development. London, U.K. Taylor & Francis. pp 35-61.
42. Tan D, Kini R, Jois S, Lim D, Xin L, Ge R. 2001. A small peptide derived from flt-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett 494(3):150-6.
43. Tian F, Zhang X, Tong Y, Yi Y, Zhang S, Li L, Sun P, Lin L, Ding J. 2005. Pe, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo. Cancer Biol Ther 4(8):874-82.
44. Tong Y, Zhang X, Tian F, Yi Y, Xu Q, Li L, Tong L, Lin L, Ding J. 2005. Philinopside a, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects. Int J Cancer 114(6):843-53.
45. Wang H, Keiser J. 1998. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circulat Res 83(8):832-40.
46. Wang S, Liu H, Ren L, Pan Y, Zhang Y. 2008. Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia 10(4):399-409.
47. Whittaker M, Floyd C, Brown P, Gearing A. 1999. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 99:2735-76.
48. Wojtowicz-Praga S, Dickson R, Hawkins M. 1997. Matrix metalloproteinase inhibitors. Investigat New Drugs 15(1):61-75.
49. Yang S, Hsieh Y, Lin C, Hsu N, Chiou H, Chou F, Chu S. 2005. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clinica Chimica Acta 354(1-2):91-9.
50. Yang S, Chu S, Liu S, Chen Y, Chang Y, Hsieh Y. 2007. Antimetastatic activities of selaginella tamariscina (beauv.) on lung cancer cells in vitro and in vivo. J Ethnopharmacol 110(3):483-9.
51. Yu Y, Li Q, Zhu Z. 2005. Nf-κb as a molecular target in adjuvant therapy of gastrointestinal carcinomas. Eur J Surgic Oncol 31(4):386-92.
52. Zhang S, Tang H, Yi Y. 2007. Cytotoxic triterpene glycosides from the sea cucumber Pseudocolochirus violaceus. Fitoterapia 78(4):283-7.